Breast cancer is a heterogeneous disease characterized by different molecular markers and clinical features, but, approximatively, 75% of BC cases are 17β‐estradiol (E2)‐dependent and express the estrogen receptor α (ERα), which sustains tumor resilience and growth [3]. Here, ESR1 is linked to neoplasm.